ACTL6A was amplified in lung squamous cell carcinoma (44.42%), cervical cancer (19.03%), esophageal carcinoma (22.58%), head and neck cancer (20.19%), and ovarian cancer (26.73%). Here, ACTL6A is linked to cervical cancer.